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Introduction
In the United States, 300,000-450,000 individuals suffer cardiac arrest each year (Callans, 2004) , the main cause for global cerebral ischemia. More than half of the patients who survive have permanent brain impairment of variable grades (Pusswald et al., 2000) . The brain injury caused by transient global cerebral ischemia is characterized by a delayed selective death of CA1 pyramidal neurons in the hippocampus (Kirino, 1982; Pulsinelli and Brierley, 1979) . This region is critically involved in spatial learning and memory, and the degeneration of pyramidal neurons results in impairment of these functions (Bendel et al., 2005; Milani et al., 1998) .
Pathophysiological mechanisms in cerebral ischemia include anaerobic glycolysis, membrane depolarization, glutamate excitotoxicity, ion imbalance, oxidative stress, activation of proteases, and inflammation (Harukuni and Bhardwaj, 2006; Rodrigo et al., 2005) . These events precede and contribute to the death of hippocampal CA1 neurons, which can be detected three days after global ischemia (Block, 1999; Kirino, 1982) . The inflammatory response after global cerebral ischemia involves, among other features, reactive microgliosis in and around the damaged area of the brain, which can be observed from the first days after reperfusion (Sugawara et al., 2002; Yasuda et al., 2011) . This process is characterized by overactivation of the microglia (the resident innate immune cells in the brain), and plays an important role in the progression of the ischemic injury through the release of cytokines and cytotoxic molecules (Block et al., 2007) .
Although some studies have shown beneficial effects of microglial activation (Lalancette-Hebert et al., 2007; Ohtaki et al., 2008) , most reports indicate that modulation of microglial activation reduces the neuronal death induced by cerebral ischemia (Franco et al., 2012; Hirko et al., 2008; Kaundal and Sharma, 2011) .
Stem cell therapy has been considered a potential therapeutic alternative for various pathologies of the central nervous system (CNS) (Hess and Borlongan, 2008; Park et al., 2010) . In particular, the transplantation of bone marrowderived cells has shown positive results in preclinical models of CNS lesions (Lee et al., 2010a; Levy et al., 2008; Zaveruchado-Valle et al., 2011) , including cerebral ischemia (Brenneman et al., 2010; de Vasconcelos Dos Santos et al., 2010; GiraldiGuimaraes et al., 2009; Vasconcelos-dos-Santos et al., 2012) . Although the mechanisms involved are still under discussion, many studies have demonstrated that transplantation of bone-marrow mononuclear cells (BMMCs) promotes neuroprotection and functional recovery of animals subjected to focal cerebral ischemia (Franco et al., 2012; Giraldi-Guimaraes et al., 2009; Yang et al., 2011) . Our aim was to investigate whether similar effects could be observed in a model of global cerebral ischemia. To our knowledge, only a few studies have investigated the effect of bone-marrow mesenchymal stem cells in preclinical models of global cerebral ischemia (Garbayo et al., 2011; Ohtaki et al., 2008; Perasso et al., 2010; Wang et al., 2008; Zheng et al., 2010) and only one study showed the biodistribution of BMMCs but did not investigate the effects of cell transplantation in the neurodegeneration and reactive microgliosis, as shown in the present paper (Makela et al., 2013) . The advantage of BMMCs is that they are easily obtained and do not need extensive culturing before use. In addition, they have proved to be safe in clinical studies of stroke (Battistella et al., 2011; Friedrich et al., 2012; Rosado-de-Castro et al., 2013a; Rosado-de-Castro et al., 2013b) .
Results

Time course of neurodegeneration in the CA1 layer after 4VO
Different models of global cerebral ischemia can lead to different temporal patterns of injury in the CA1 layer of the hippocampus. In our model we investigated the time course of neuronal degeneration in the pyramidal layer of CA1, assessing the number of Fluoro-Jade C (FJ-C)-positive cells 3, 7 and 14 DAI after global cerebral ischemia. We observed an increase in the number of FJ-C-positive cells from 3 to 7 days after ischemia (from 17.170.89 cells/mm at 3 DAI to 159.1722.8 cells/mm at 7 DAI). This number decreased in the following week (114.3716.5 cells/mm) (p ¼0.0001; Fig. 1 ). We also observed the presence of FJ-C positive cells in the dentate gyrus as well as in other regions of the brain known to be vulnerable in this model of ischemia, such as the striatum and cerebral cortex (data not shown).
Characterization and biodistribution of the transplanted BMMCs
The cellular fraction obtained from the bone marrow after separation by density gradient in Histopaque 1083 was heterogeneous, with different cell populations. Analysis by flow cytometry showed that approximately 4% of the analyzed fraction consisted of hematopoietic precursor cells (CD45+ and CD34+); 8.0370.39% by monocytes (CD45+ and CD11b/c+); 48.8713.2% by granulocytes (CD45+/Granulocytes) and 35.973.5% by immature hematopoietic stem cells (CD45+ and CD90 +).
To investigate the biodistribution and homing of the injected BMMCs, we labeled the cells with 99m Technetium ( 99m Tc) and injected these cells 1 or 3 DAI. The animals were examined by whole-body scintigraphic imaging 2 h after transplantation. We observed activity in the injection site ( Fig. 2A and B: non-ischemic rats; C and D: ischemic rats injected 1 DAI; E and F: ischemic rats injected 3 DAI) and in the liver and spleen ( Fig. 2G and H) but no activity was distinguished in the brain. After imaging, the animals (injected 3 DAI) were euthanized, and the brains isolated and analyzed by gamma-well counting. We observed a difference between non-ischemic and ischemic groups (2.47 1.6 Â 10 −2 % ID/g vs. 11.876.5 Â 10 −2 % ID/g; p¼ 0.0159; Fig. 2I ), suggesting that, although in very low quantity, global ischemic injury led to an increase in the uptake of 99m TcBMMCs in the brain region. However, the short half-life of 99m Tc did not allow us to follow the cells for more than 24 h after injection. In order to investigate the fate of the injected cells for longer periods, BMMCs were labeled with CellTrace ™ , transplanted 1 or 3 DAI and the presence of labeled cells in b r a i n r e s e a r c h 1 5 2 2 ( 2 0 1 3 ) 1 -1 1 the hippocampal region was analyzed 6 or 4 days after injection. A few labeled cells were found in the hippocampus of the ischemic animals ( 
2.3.
BMMC transplantation has a neuroprotective effect in the CA1 layer
To investigate whether BMMCs transplantation could promote neuroprotection in the CA1 region of the hippocampus in our model, we injected BMMC at 1 DAI or 3 DAI and the animals were allowed to survive up to 7 DAI. In non-ischemic animals, FJ-C-positive cells are not present (Fig. 3A) . In the ischemic animals, the number of FJ-C-positive cells at 7 DAI was significantly reduced in the treated animals (BMMC 1 DAI: 66.7710.3 cells/mm; BMMC 3 DAI: 78.3716.6 cells/mm) compared with the untreated animals (177.6769.9 cells/mm) (Fig. 3B-D) . No difference in neurodegeneration was observed between animals who received BMMCs at 1 DAI or at 3 DAI (p¼ 0.0004; Fig. 3E ).
2.4.
BMMCs transplantation reduced microglial activation in the CA1 layer Since modulation of the neuroinflammatory response has been suggested as a possible mechanism of action of bone marrow-derived cell therapies, we evaluated in our model the presence of activated microglia/macrophages, using immunohistochemistry for the CD68 antigen (ED1) in areas of neurodegeneration at 7 DAI. In ischemic animals we observed the presence of ED-1-positive cells in the CA1 layer of the hippocampus ( 
The number of ED-1-positive cells in the groups treated with BMMCs was smaller than in the group that received only saline (p¼ 0.0058; Fig. 4E ).
Discussion
Cerebral ischemia can be divided as global, focal, and multifocal ischemia. Global ischemia occurs when cerebral blood flow (CBF) is reduced throughout all of the brain, whereas focal ischemia is represented by a reduction in blood flow to a very distinct, specific brain region. In multifocal ischemia, there is a patchy pattern of reduced CBF (Traystman, 2003) . Most ischemic strokes occur due to the occlusion of a cerebral artery by a thrombus. The region of the brain supplied by the affected artery has a central area of infarction called core or center and an area around the center area called the penumbra, the latter being a potential therapeutic target (Green, 2003) . In this paper, we use the 4VO method, a specific model of global cerebral ischemia, which causes selective death of CA1 pyramidal neurons in layer of the hippocampus (Pulsinelli and Brierley, 1979 ). In our model, we found a peak of neuronal degeneration in the CA1 hippocampal layer 7 days after global ischemia, differing from previous reports. Bendel and colleagues, for example, reported a peak in neurodegeneration at 14 DAI (Bendel et al., 2005) in a model that differs from ours mainly in the time of occlusion (11 min of carotid occlusion) and the use of two vessels with hypotension (two-vessel occlusion). We suggest that different models of global cerebral ischemia can lead to different temporal patterns of injury in the CA1 layer of the hippocampus, and this pattern must be investigated in each model. One of our goals was to investigate whether the BMMCs injected into the carotid artery were able to reach the affected region in the hippocampus. In the present study we were able Tc-BMMCs 2 h after intra-arterial injection in non-ischemic (n ¼ 5) and ischemic (n ¼4) rats injected 3 DAI by gamma-well counting (I). Tracer activity is expressed as the percentage of injected dose per gram of organ (%ID/g) n po0.05 Mann-Whitney test; histological images of BMMCs labeled with CellTrace (red) in the CA1 layer 6d (J) and 4d (K) after intra-arterial injection. Inset (K′) with confocal orthogonal image showing CellTrace-positive cell (red) around the nuclei (green). Scale bar¼50 lm.
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to acquire scintigraphies at a dedicated small animal SPECT/ CT camera, which allows better tracking of the cells. Nevertheless, homing could not be distinguished in the brain in the scintigraphies. Therefore, the uptake of 99m Tc-BMMCs in the brains of non-ischemic and ischemic animals (injected 3 DAI) was analyzed by gamma-well counting and showed very low activity in the brain. Although homing in the brain was low, there was higher uptake in the brains of ischemic animals compared with non-ischemic animals, suggesting that the global cerebral ischemic event generates an environment that favors homing of transplanted cells to the brain at least 2 h after injection. Our group recently reported a significant increase in uptake of radioactivity in the ischemic hemisphere of animals transplanted with 99m
Tc -BMMCs , 2013b) . Importantly, the same labeling technique was used in the focal ischemia study and in our model of global ischemia, but we were able to show a preferential homing to the ischemic brain as early as 2 h after transplantation, suggesting that different lesions may lead to differences in cell homing and biodistribution. The animal and clinical findings indicate that, although greater relative homing may occur to ischemic areas, the total uptake is low in comparison to the whole-body. Furthermore, to confirm the presence of transplanted cells in the brain, we carried out CellTrace labeling and found few CellTrace-positive cells in the CA1 layer of ischemic animals injected 1 or 3 DAI. These findings seem to accord with previous studies that detected the migration of a small fraction of the transplanted bone-marrow cells to the brain in models of focal or global cerebral ischemia (Franco et al., 2012; Makela et al., 2013; Prabhakar et al., 2010; Vasconcelos-dos-Santos et al., 2012; Zheng et al., 2010) .
Several factors are responsible for the attraction of the transplanted cells into the ischemic brain. Shen and colleagues (Shen et al., 2007) showed that after cerebral ischemia there is increased expression of stromal-cell-derived-factor-1 (SDF-1) in the infarct region and a concomitant increase in the specific receptor for this factor, CXCR4 present in bone marrow-derived cells. Overexpression of this factor was also observed by Olstorn and colleagues (Olstorn et al., 2011) strictly in the CA1 layer of the hippocampus of animals subjected to global cerebral ischemia. This suggests that the SDF-1 acts to favor the homing of transplanted stem cells in different ways to the injured brain area.
However, several studies have shown that the presence of cells in the ischemic brain is not necessary for the beneficial effects of cell therapy after intravascular transplantation to be observed in ischemic animals (Borlongan et al., 2004; Brenneman et al., 2010; Kamiya et al., 2008) , and it has been suggested that BMMCs may have systemic effects related to the presence of these cells in organs such as the spleen (Keimpema et al., 2009; Yang et al., 2011) .
Analysis of the neurodegeneration in the CA1 layer after BMMCs transplantation indicated a reduction in the number of FJ-C-positive neurons in ischemic animals injected at 1 or 3 DAI and euthanized at 7 DAI, showing that the neuroprotective effect is maintained even when the transplant is performed in later periods after the ischemic event. Our data coincide with previous studies which showed that the intravascular transplantation of BMMCs in models of stroke reduces neurodegeneration in ischemic animals (Brenneman et al., 2010; Franco et al., 2012; Giraldi-Guimaraes et al., 2009; Kamiya et al., 2008; Nakano-Doi et al., 2010) .
Few studies have shown the effects of bone marrowderived cell therapy in preclinical models of global cerebral ischemia (Garbayo et al., 2011; Ohtaki et al., 2008; Perasso et al., 2010; Wang et al., 2008; Zheng et al., 2010) , and all these studies used bone-marrow mesenchymal stem cells (MSCs). The beneficial effect observed in our study was similar to that observed in studies using bone-marrow MSCs in this model (Garbayo et al., 2011; Perasso et al., 2010; Zheng et al., 2010) . In the present study, we used the mononuclear fraction of bone marrow, since in a clinical setting the use of these cells has several advantages over MSC therapy. For example, BMMCs transplantation shortens the interval between the onset of ischemia and cell transplantation, since MSCs require approximately 30 days in culture in order to obtain a sufficient number of cells, as shown in a clinical trial using autologous transplantation in patients after acute ischemic stroke (Bang et al., 2005; Lee et al., 2010a; Lee et al., 2010b) . Therefore, cell transplantation could be applied in less time for patients suffering for conditions that may lead to global cerebral ischemia such as cardiac arrest. Furthermore, several studies have reported that transplanted BMMCs are safe in stroke patients (Barbosa da Fonseca et al., 2009; Barbosa da Fonseca et al., 2010; Battistella et al., 2011; Friedrich et al., 2012; Mendonca et al., 2006; Savitz et al., 2011) .
The mechanisms of action that may result in the neuroprotective effect observed after bone marrow-derived cell therapy remain incompletely characterized. However, it is believed that these cells act indirectly, through paracrine mechanisms. In our study, we investigated a possible immunomodulatory effect of BMMCs transplantation. We showed that BMMCs transplantation reduced the reactive microgliosis observed in the CA1 layer of the hippocampus of ischemic animals. It has been suggested that the modulation of the inflammatory response caused by global or focal cerebral ischemia contributes to the neuroprotective effect observed after cell therapy (Brenneman et al., 2010; Franco et al., 2012; Hirko et al., 2008) . Ohtaki and collaborators (Ohtaki et al., 2008) reported that the injection of human MSCs in the hippocampus resulted in down-regulation of 10% of ischemia-induced genes, most of them involved in inflammatory and immune responses. Ohtaki and collaborators also reported that cell therapy was able to reduce neuronal death in the hippocampus, indicating a possible relationship between the modulation of the inflammatory response and the neuroprotective effect, as also found in our study. Similarly, the immunomodulatory effect of BMMCs was reported by Brenneman et al. (2010) in an animal-stroke model; they found that intra-arterial injection of BMMCs reduced the infarct volume and promoted functional recovery of ischemic animals. Furthermore, BMMCs therapy reduced the levels of several proinflammatory cytokines (IL-1α, IL-1β, IL-2, IL-6 and TNF-α) while increasing the levels of an antiinflammatory cytokine (IL-10) (Brenneman et al., 2010) .
Conclusions
Our data suggest that BMMCs reduce activation of microglia/ macrophages, and result in a neuroprotective effect characterized by a reduction of cell death in the CA1 layer of the hippocampus. These results suggest that the use of BMMCs may be a possible therapeutic tool to modulate the effects of inflammatory cells, reduce CA1 pyramidal neuronal death, and consequently decrease the functional deficit resulting from global cerebral ischemia.
Experimental procedures
Animals
Adult male Wistar rats (250-350 g) were maintained in a temperature-and light-controlled environment. All procedures were carried out in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals (NIH Publication no. 80-23) and were approved by the Institutional Committee for the Use of Experimental Animals (IBCCF 021).
5.2.
Global cerebral ischemia
Global cerebral ischemia was induced using the four-vessel occlusion method (4VO) (Pulsinelli and Brierley, 1979) with some modifications. The rats were anesthetized with isofluorane in oxygen administered by a mask attached to a vaporizer. Rectal temperature was monitored before, during and after ischemia, and maintained at 37.071.0 1C using a heat lamp. Briefly, the day before surgery, an incision was made behind the occipital bone directly overlying the first two cervical vertebrae. The paraspinal muscles were separated from the midline, the right and left alar foramina of the first cervical vertebrae were exposed, and the vertebral arteries were permanently occluded by electrocauterization. Twenty-four hours later, the animals were again anesthetized, the common carotid arteries were exposed through a ventral midline neck incision and occluded for 17 min using aneurism clips (Fine Science Tools, Inc.). Anesthesia was discontinued immediately after initiation of the occlusion. After the procedure, the skin was sutured and the animals were kept warm under a heat lamp and returned to the colony room after they recovered from the surgery. Animals were excluded if they failed to show pupillary dilation and loss of the righting reflex during the cerebral ischemia. They also were excluded from the study if they failed to recover (i.e., resume normal grooming) within 30 min or if they showed behavioral manifestations such as abnormal vocalization when handled, had generalized convulsions, or showed hypoactivity.
BMMCs isolation
BMMCs were isolated from the tibias and femurs of normal syngeneic donor rats. Briefly, bone marrow was aspirated from the bones and dissociated with serum-free DMEM-F12 (Gibco BRL, Grand Island, NY, USA) and collected in sterile tubes. Bone-marrow cells were then mechanically dissociated, centrifuged for 5 min (250 Â g), and resuspended in 4 ml of DMEM-F12. This volume was gently added over 4 ml of Histopaque 1083 (Sigma-Aldrich, São Paulo, Brazil) and centrifuged for 30 min (400 Â g). The cells were collected from the mononuclear cell region and washed with phosphatebuffered saline (PBS), pH 7.4 in three consecutive centrifugations at 250 Â g (5 min). Following a final centrifugation, approximately 3 Â 10 7 BMMCs were suspended in 300 μl of saline and either injected immediately in the animals submitted to the histological analysis, or labeled for localization analysis.
Analysis of BMMCs using flow cytometry
The BMMC population was characterized by flow cytometry. Cells were incubated for 20 min with the following antibodies: anti-CD34-phycoerythrin (PE, Santa Cruz Biotechnology); anti-CD11b/c-FITC (fluorescein isothiocyanate; Caltag Laboratories-Invitrogen), anti-CD45-PE-cyanine 5 (PE-CY5), antiGran-1-FITC and anti-CD90-PE (BD Biosciences, San Jose, CA, USA). Subsequently, we used a lysing solution (BD Lysing Solution, BD Biosciences) to lyse erythrocytes, and fixed the cells. Then, the cells were washed in PBS prior to analysis in a flow cytometer (BD FACSAria, BD Biosciences). All antibody dilutions were 1:100 in PBS. Data analyses were performed using Infinicyt 1.2 software (Cytognos).
BMMC labeling with 99m
Tc or cell trace
BMMCs were labeled with 99m Tc following protocols described previously Quintanilha et al., 2008; Vasconcelos-dos-Santos et al., 2012) . Briefly, 500 μL of sterile SnCl 2 solution was added to the cell suspension in phosphate-buffered saline (PBS), and the mixture was incubated at room temperature for 10 min. Then, 5 mCi of 99m Tc was added and the incubation continued for another 10 min. After centrifugation (500 Â g for 5 min), the supernatant was removed and the cells were washed three times with PBS. Viability of the labeled cells was assessed by the trypan blue exclusion test, and was estimated to be greater than 93% in all cases. Labeling efficiency (%) was calculated by the activity in the pellet divided by the sum of the radioactivity in the pellet plus supernatant, and was estimated to be greater than 90% in all cases. Approximately 3 Â 10 7 99m Tc-BMMCs were injected through the left common carotid artery (IA) immediately after labeling in ischemic rats, 1 or 3 DAI, and in nonischemic rats. Whole-body scintigraphies were performed in these animals for qualitative biodistribution in a dedicated small animal SPECT/CT camera (Triumph, Gamma-medica ideas, Canada) equipped with a high-resolution collimator and diagnostic CT. To compare the radioactivity in the brains of ischemic animals injected 3 DAI (n¼ 4) and nonischemic animals (n ¼5), after the completion of the images, the animals were euthanized and their brains removed and weighed. The total radioactivity injected in each animal and the remaining radioactivity in each brain was measured in a gamma counter (Cobra II Auto-Gamma, Packard, USA 
Histological and immunohistochemical analysis
To analyze the time course of neurodegeneration in the CA1 layer, the animals were allowed to survive for 3, 7 or 14 days after global cerebral ischemia (n¼ 3 in each group). To analyze the effect of cell therapy in neurodegeneration and reactive microgliosis, the animals were allowed to survive for 7 days after global cerebral ischemia. Animals was euthanized and fixed with 4% paraformaldehyde in 0.1 M phosphate-buffered saline, and the brains were removed. After cryoprotection, coronal sections (20 μm thick) were cut beginning 3.6 mm from the bregma. The sections were then reacted for FluoroJade C (FJ-C Histo-Chem Inc.) staining, in accordance to the manufacturer's instructions (Schmued et al., 2005) . For analysis of the microglial activation, the sections were subjected to blocking with 5% normal goat serum for 30 min. Afterwards, these sections were incubated with a primary antibody, CD-68 (ED1; 1:100; Serotec, Dusseldorf, Germany) at 4 1C overnight, followed by secondary antibody, Alexa Fluor 488-conjugated goat anti-mouse (1:200; Invitrogen) for 2 h at room temperature. For assessment of tissue damage, three sections containing regions at a distance of 3.6-4.3 mm bregma were stained with Fluoro-Jade C (saline, n ¼6; BMMCs 1 DAI, n¼4; BMMCs 3 DAI, n¼ 5) or immunostained for ED1 (saline, n¼ 4; BMMCs 1 DAI, n¼ 3; BMMCs 3 DAI, n ¼3), as previously described. The stained cells were counted in the CA1 layer of the hippocampus, under 20 Â magnification, and expressed as cells/mm for Fluoro-Jade and cells/mm 2 for ED-1. Fluorescence was documented using confocal imaging microscopy (Zeiss LSM 510META; Carl Zeiss, Gottingen, Germany) or Apotome microscopy (Carl Zeiss).
Statistical analysis
For statistical comparisons among groups we used Student's t or Mann-Whitney tests. For analyses that contained more than two variables, we used one-way ANOVA followed by Bonferroni post-hoc. Po0.05 was considered statistically significant. All analyses were performed using GraphPad Prism version 5 for Windows (GraphPad Software).
Acknowledgments
This study was supported by grants from Ministry of Health (MS/SCTIE/DECIT), Conselho Nacional r e f e r e n c e s
